Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study
Kaeley G, Schett G, Conaghan P, Mcgonagle D, Behrens F, Goupille P, Gaillez C, Parikh B, Meng X, Bakewell C (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 3808-3811
Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY
Authors with CRIS profile
Involved external institutions
University of Leeds
United Kingdom (GB)
University of Florida
United States (USA) (US)
Goethe-Universität Frankfurt am Main
Germany (DE)
Centre Hospitalier Régional Universitaire de Tours
France (FR)
Novartis AG
Switzerland (CH)
Intermountain Healthcare
United States (USA) (US)
United Kingdom (GB)
University of Florida
United States (USA) (US)
Goethe-Universität Frankfurt am Main
Germany (DE)
Centre Hospitalier Régional Universitaire de Tours
France (FR)
Novartis AG
Switzerland (CH)
Intermountain Healthcare
United States (USA) (US)
How to cite
APA:
Kaeley, G., Schett, G., Conaghan, P., Mcgonagle, D., Behrens, F., Goupille, P.,... Bakewell, C. (2021). Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study. In ARTHRITIS & RHEUMATOLOGY (pp. 3808-3811). HOBOKEN: WILEY.
MLA:
Kaeley, Gurjit, et al. "Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2021. 3808-3811.
BibTeX: Download